John Rush, MD Professor of Psychiatry, University of Texas Southwestern Medical School Principal Investigator and Study Director, STAR*D Trial Dr. Rush has disclosed that he was or is a consultant for Bristol Myers Squibb, Cyberonics, GlaxoSmithKline, Neuronetics, Ono, Organon; was or is a member of the speakers bureau of Cyberonics, Forest and GlaxoSmithKline; and was or is a stock shareholder of Pfizer Pharmaceuticals. The editors of The Carlat Psychiatry Report have closely reviewed the content of Dr. Rush’s interview and have determined that there are no financial conflicts of interest regarding this educational activity.